Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000726802 | SCV000571388 | likely benign | not provided | 2021-10-26 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000726802 | SCV000703147 | uncertain significance | not provided | 2016-11-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002367644 | SCV002661659 | likely benign | Inborn genetic diseases | 2018-10-24 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003985364 | SCV004115101 | uncertain significance | CACNA1A-related disorder | 2022-12-22 | criteria provided, single submitter | clinical testing | The CACNA1A c.6648_6656del9 variant is predicted to result in an in-frame deletion (p.His2217_His2219del). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.013% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-13319693-ATGGTGGTGG-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |